Tag: Instis

First approved in 2007, integrase strand transfer inhibitors (INSTIs) have revolutionized HIV treatment, becoming a cornerstone of modern antiretroviral therapy regimens. These potent medications, like dolutegravir and bictegravir, work by targeting a critical step in the HIV life cycle, providing effective viral suppression.

Antiretroviral therapy (ART) has transformed HIV from a fatal diagnosis into a manageable chronic condition, largely due to innovative drug classes like integrase inhibitors. These medications specifically target the HIV integrase enzyme, effectively preventing the virus from multiplying and integrating its genetic material into human cells. The development of this drug class has significantly improved treatment outcomes and reduced the likelihood of viral resistance.